Turning Point Brands, Inc. (TPB)
NYSEConsumer StaplesTobaccoSnapshot 2026-09-09
$73.21-1.74%
Close 2026-09-09 · 1-day change
NYSEConsumer StaplesTobaccoSnapshot 2026-09-09
Intact: The reason to own it still holds.
Turning Point Brands grows revenue about 15% a year. It raised 2026 revenue guidance to $215 million. The company invests in Modern Oral sales to drive growth. Profitability is stable with EBITDA guidance introduced.
Revenue growth could slow below 7%. Profit margins might shrink. Rising costs or weak demand could hurt earnings.
The price is about 52% above our fair value near $58. Analysts expect 15% revenue growth. We see growth but think the price is too high.
Breaks if: Modern Oral sales decline or fail to grow in FY26
Breaks if: EBITDA falls significantly below $70M in FY26
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a durable compounder with a focus on expanding market share in the Modern Oral segment. The current thesis state is intact, supported by recent earnings beats, but faces challenges from sector headwinds and elevated risks.
The market seems to assume a neutral valuation with a slight premium compared to peers. There is an expectations gap, indicating that some growth is already priced in, but the overall sentiment reflects a fragile execution quality.
Management's focus on growing Modern Oral sales is showing positive results, with significant revenue growth reported. However, the mixed progress toward Adjusted EBITDA guidance and increased marketing expenses suggest that fundamentals may face pressure in the near term.
The long-term thesis hinges on management's ability to meet guidance and the performance of sector peers. Additionally, macroeconomic factors like inflation could impact the broader Consumer Staples sector, influencing TPB's performance.
The most important moves since the prior daily snapshot.
Yes, our read has strengthened. The latest earnings beat supports a positive outlook. Additionally, the company aims to grow Modern Oral sales and expand market share. This aligns with its growth objectives and reinforces the thesis.
as of 2026-09-09
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Management introduced full-year 2026 EBITDA guidance, indicating a focus on profitability and financial performance.
Breaks if: YoY revenue growth falls below 7% in FY26
Over the next 1 to 3 years, TPB's outlook is shaped by its growth initiatives and sector dynamics, but it must navigate risks and execution challenges. Not investment advice.